Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This proof of concept trial aims to assess whether the combination of IRE with Nivolumab is
safe and effective to treat metastatic pancreatic cancer, based on the available preliminary
evidence that IRE is able to cause a systemic anti-tumor immune response (i.e. abscopal
effect), which may enhance the effect of subsequent Nivolumab treatment. In addition, the
trial aims to clarify the systemic effects of IRE over time and thereby to provide more
insight in the mechanism of work of the technique.
Phase:
Phase 2
Details
Lead Sponsor:
Swiss Group for Clinical Cancer Research University Hospital, Basel, Switzerland